Eiko Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/05/2026 ,inter alia, to consider and approve The Audited Standalone and ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Eiko Lifesciences Ltd has informed BSE that a Board Meeting is scheduled for 26th May 2026 to consider and approve the Audited Standalone and Consolidated Financial Results for Q4 and the financial year ending 31st March 2026. This is a routine regulatory filing under Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company has also confirmed that the Trading Window is already closed since 1st April 2026 for all Designated Persons and will remain closed till 48 hours after the results are declared. The filing was made by Company Secretary Chintan Doshi on 21st May 2026.
This is a standard pre-results announcement notice. No material information is disclosed in this filing itself — actual financial numbers will be available after the meeting. The closure of the trading window indicates compliance with insider trading regulations.